ETON News and Press, Eton Pharmaceutcials Inc. From 03/07/23

DEER PARK, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter 2022 financial results on Thursday, March ...

Summary A number of VBR "green energy" picks have popped higher in January, pulling investment returns for the group of past picks strongly higher. A performance review of 46 previous selections since late June is discussed. I continue to refine the search and formula ideas for iden...

Penny Stocks To Watch: January 2023 Edition This week has already been wild, and we aren’t even halfway there yet. Despite what broader markets have done, penny stocks continue performing for traders. The unique makeup of these cheap stocks tends to see company-specific speculation...

Eton Pharmaceuticals ( NASDAQ: ETON ) announced Wednesday that the FDA accepted its new drug application (NDA) response for dehydrated alcohol injection as a treatment for methanol poisoning. The agency has granted June 27, 2023, as the PDUFA target action date for its decision. &...

-- Product previously granted orphan drug designation for methanol poisoning -- -- Application assigned a PDUFA date of June 27, 2023 -- DEER PARK, Ill., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovativ...

Eton Pharmaceuticals, Inc. (ETON) Q3 2022 Earnings Conference Call November 10, 2022 04:30 PM ET Company Participants David Krempa - Senior Vice President, Business Development & Investor Relations Sean Brynjelsen - Chief Executive Officer James Gruber - Chie...

Eton Pharmaceuticals press release ( NASDAQ: ETON ): Q3 GAAP EPS of -$0.12. Revenue of $3.22M (+312.8% Y/Y). For further details see: Eton Pharmaceuticals GAAP EPS of -$0.12, revenue of $3.22M

Q3 2022 revenue of $3.2 million, product sales and royalty revenue up 315% from prior year and 37% from Q2 2022 Strong sales growth of ALKINDI SPRINKLE® and Carglumic Acid Third commercial product, Betaine Anhydrous, added to rare disease portfolio DEER PARK, Ill., ...

Summary Harrow Health, Inc. is a well-managed ophthalmic medicines business. The company has remained profitable for a number of years. Harrow Health expects to double revenues in 2-3 years. For further details see: Harrow Health: Profitable Ophthalmi...

DEER PARK, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2022 financial results on Thursday, No...